Isocitrate dehydrogenase 1 and 2 mutations in gliomas |
| |
Authors: | Magdalena Megova Jiri Drabek Vladimira Koudelakova Radek Trojanec Ondrej Kalita Marian Hajduch |
| |
Institution: | 1. Laboratory of Experimental Medicine, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital in Olomouc, Olomouc, Czech Republic;2. Department of Neurosurgery, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital in Olomouc, Olomouc, Czech Republic |
| |
Abstract: | Over the past few years, new biomarkers have allowed a deeper insight into gliomagenesis and facilitated the identification of possible targets for glioma therapy. Isocitrate dehydrogenase (IDH) 1 and IDH2 mutations have been shown to be promising biomarkers for monitoring disease prognosis and predicting the response to treatment. This review summarizes recent findings in this field. Web of Science, Science Direct, and PubMed online databases were used to search for publications investigating the role of IDH in glioma. References were identified by searching for the keywords “IDH1 or IDH2 and glioma and diagnostic or predictive or prognostic” in papers published from January, 2008, to April, 2014. Only papers in English were reviewed. Publications available only as an abstract were not included. IDH1/2 mutations are tightly associated with grade II and III gliomas and secondary glioblastomas, with better prognosis and production of a recently described oncometabolite, 2‐hydroxyglutarate (2HG). Although the contradictory positive effect of IDH mutation on prognosis and negative role of 2HG in tumor transformation remain unresolved, the future direction of personalized treatment strategies targeted to glioma development is likely to focus on IDH1/2 mutations. © 2014 Wiley Periodicals, Inc. |
| |
Keywords: | isocitrate dehydrogenase IDH1 IDH2 glioma 2‐hydroxyglutarate prognostic marker predictive marker |
|
|